Claims

1. A compound of the formula I,



I

wherein

R^1 is selected from the series consisting of hydrogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-, Ar and Ar-$(C_1$-$C_4)$-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-, Ar, Ar-$(C_1$-$C_4)$-alkyl-, $(C_1$-$C_4)$-alkyl-O-, $(C_3$-$C_7)$-cycloalkyl-O-, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-O-, Ar-O- and Ar-$(C_1$-$C_4)$-alkyl-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen, fluorine and $(C_1$-$C_6)$-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a $(C_3$-$C_7)$-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

R^{11}, R^{12}, R^{13} and R^{14} are independently of each other selected from the series consisting of hydrogen and $(C_1$-$C_4)$-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two

identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-, cyano and $(C_1$-$C_4)$-alkyl-O-;

V is selected from the series consisting of R^{12}-N(R^{13})-, and in this case G and M are not present, or
V is selected from the series consisting of -N(R^{14})-, -N(R^{14})-$(C_1$-$C_4)$-alkyl-, -O- and -O-$(C_1$-$C_4)$-alkyl-, and in this case

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, cyano and $(C_1$-$C_4)$-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14})- or -O-, and

M is selected from the series consisting of R^{11}-O-C(O)- and R^{12}-N(R^{13})-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

2. A compound of the formula I according to claim 1, wherein

R^1 is selected from the series consisting of hydrogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, Ar and Ar-$(C_1$-$C_4)$-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-, Ar,

Ar-(C_1-C_4)-alkyl-, (C_1-C_4)-alkyl-O-, (C_3-C_7)-cycloalkyl-O-, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-O-, Ar-O- and Ar-(C_1-C_4)-alkyl-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen and (C_1-C_6)-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a (C_3-C_7)-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

R^{11}, R^{12}, R^{13} and R^{14} are independently of each other selected from the series consisting of hydrogen and (C_1-C_4)-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-, cyano and (C_1-C_4)-alkyl-O-;

V is selected from the series consisting of -N(R^{14})-, -N(R^{14})-(C_1-C_4)-alkyl- and -O-(C_1-C_4)-alkyl-, and

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl, cyano and (C_1-C_4)-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14})-, and

M is selected from the series consisting of R^{11}-O-C(O)- and R^{12}-N(R^{13})-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or

more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

3. A compound of the formula I according to one or more of claims 1 and 2, wherein

R^1 is selected from the series consisting of (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, Ar and Ar-(C_1-C_4)-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, (C_1-C_4)-alkyl, Ar, Ar-(C_1-C_4)-alkyl-, (C_1-C_4)-alkyl-O-, (C_3-C_7)-cycloalkyl-O-, Ar-O- and Ar-(C_1-C_4)-alkyl-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen and (C_1-C_6)-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a (C_3-C_7)-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

R^{11}, R^{12}, R^{13} and R^{14} are independently of each other selected from the series consisting of hydrogen and (C_1-C_4)-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl, (C_3-C_7)-cycloalkyl and (C_1-C_4)-alkyl-O-;

V is selected from the series consisting of -N(R^{14})- and -N(R^{14})-(C_1-C_4)-alkyl-, and

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl and (C_1-C_4)-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14})-, and

M is selected from the series consisting of R^{11}-O-C(O)- and R^{12}-N(R^{13})-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

4. A compound of the formula I according to one or more of claims 1 to 3, wherein

R^1 is selected from the series consisting of (C_1-C_4)-alkyl, Ar and Ar-(C_1-C_4)-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, (C_1-C_4)-alkyl, Ar, Ar-(C_1-C_4)-alkyl-, and Ar-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen and (C_1-C_6)-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a (C_3-C_7)-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

R^{11} and R^{14} are independently of each other selected from the series consisting of hydrogen and $(C_1$-$C_4)$-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl and $(C_1$-$C_4)$-alkyl-O-;

V is selected from the series consisting of $-N(R^{14})-$ and $-N(R^{14})-(C_1$-$C_4)$-alkyl-, and

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl and $(C_1$-$C_4)$-alkyl-O-, provided that G is not a direct bond if V is $-N(R^{14})$, and

M is R^{11}-O-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

5. A compound of the formula I according to one or more of claims 1 to 4, wherein

R^1 is selected from the series consisting of $(C_1$-$C_4)$-alkyl, Ar and Ar-$(C_1$-$C_4)$-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, $(C_1$-$C_4)$-alkyl, Ar- and Ar-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen and $(C_1$-$C_6)$-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a $(C_3$-$C_7)$-cycloalkane ring which is unsubstituted or substituted by one or more fluorine substituents;

R^{11} and R^{14} are independently of each other selected from the series consisting of hydrogen and $(C_1$-$C_4)$-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl and $(C_1$-$C_4)$-alkyl-O-;

V is selected from the series consisting of -N(R^{14})- and -N(R^{14})-$(C_1$-$C_4)$-alkyl-,

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl and $(C_1$-$C_4)$-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14}), and

M is R^{11}-O-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

6. A compound of the formula I according to one or more of claims 1 to 5, which is selected from the series consisting of

4-({2-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid,

4-({2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid,

4-({2-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazol-3-ylmethoxy]-acetylamino}-methyl)-benzoic acid,

4-({2-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazol-3-ylmethoxy]-butyrylamino}-methyl)-benzoic acid,

4-({2-[1-(2-Chloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid,

4-({2-[1-(4-Chloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid,

4-({2-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazol-3-ylmethoxy]-propionylamino}-methyl)-benzoic acid,

4-{2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-propionylamino}-benzoic acid,

4-{2-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazol-3-ylmethoxy]-3-methyl-butyrylamino}-benzoic acid,

4-{2-[1-(4-Chloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-propionylamino}-benzoic acid,

4-[2-(3-Naphthalen-2-yl-1-phenyl-1H-pyrazol-4-ylmethoxy)-propionylamino]-benzoic acid,

4-{2-[1-(2-Chloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-propionylamino}-benzoic acid,

4-[2-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethoxy)-propionylamino]-benzoic acid,

4-[2-(1,3-Diphenyl-1H-pyrazol-4-ylmethoxy)-propionylamino]-benzoic acid,

4-{2-[1-Benzyl-3-(3-methoxy-phenyl)-1H-pyrazol-4-ylmethoxy]-propionylamino}-benzoic acid,
4-{2-[5-(4-Fluoro-phenoxy)-1-methyl-3-phenyl-1H-pyrazol-4-ylmethoxy]-propionylamino}-benzoic acid,
4-{2-[3-(4-Cyclohexyl-phenyl)-1-phenyl-1H-pyrazol-4-ylmethoxy]-propionylamino}-benzoic acid,
4-[2-(1-Phenyl-3-thiophen-2-yl-1H-pyrazol-4-ylmethoxy)-propionylamino]-benzoic acid, and
4-[2-(1,5-Diphenyl-1H-pyrazol-3-ylmethoxy)-propionylamino]-benzoic acid,
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

7. A compound of the formula I or a pharmaceutically acceptable salt thereof according to one or more of claims 1 to 6 for use as medicament.

8. A compound of the formula I or a pharmaceutically acceptable salt thereof according to one or more of claims 1 to 6 for use in the treatment of a disease responsive to the inhibition of the LPA receptor LPAR5 or the reduction or inhibition of platelet aggregation or thrombus formation or the reduction or inhibition of activation of mast cells or the reduction or inhibition of activation of microglial cells.

9. A compound of the formula I or a pharmaceutically acceptable salt thereof according to one or more of claims 1 to 6 for use in the treatment of thromboembolic diseases, deep vein thrombosis, venous or arterial thromboembolism, thrombophlebitis, coronary or cerebral arterial thrombosis, cerebral embolism, renal embolism, pulmonary embolism, disseminated intravascular coagulation, cardiovascular disorders, transient ischemic attacks, strokes, acute myocardial infarction, unstable angina, chronic stable angina, peripheral vascular disease, preeclampsia/eclampsia, thrombotic cytopenic purpura, inflammatory disorders, hyperalgesia, asthma, multiple sclerosis, inflammatory pain, angiogenesis, atherothrombosis, allergic responses, or restenoses.

10. A compound of the formula I or a pharmaceutically acceptable salt thereof according to one or more of claims 1 to 6 for use in the treatment of abnormal thrombus formation, acute myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication, bypass grafting of the coronary or peripheral arteries, vessel luminal narrowing, restenosis post coronary venous angioplasty, maintenance of vascular access patency in long-term hemodialysis patients, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee or hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulatopathy occurring in vascular systems during septic shock, viral infections or cancer.

11. A compound of the formula I or a pharmaceutically acceptable salt thereof according to one or more of claims 1 to 6 for use in the treatment of inflammatory pain, asthma, angiogenesis, demyelating diseases of the central nervous system or the peripheral nervous system, multiple sclerosis, transverse myelitis, optic neuritis, Devic's disease, Guillain-Barre syndrome or chronic inflammatory demyelinating polyneuropathy.

12. A pharmaceutical composition comprising a compound of the formula I or a pharmaceutically acceptable salt thereof according to one or more of claims 1 to 6, and a pharmaceutically acceptable carrier.

Claims

1. A compound of the formula I,



I

wherein

R^1 is selected from the series consisting of hydrogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, $(C_3\text{-}C_7)$-cycloalkyl-$(C_1\text{-}C_4)$-alkyl-, Ar and Ar-$(C_1\text{-}C_4)$-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, halogen, $(C_1\text{-}C_4)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, $(C_3\text{-}C_7)$-cycloalkyl-$(C_1\text{-}C_4)$-alkyl-, Ar, Ar-$(C_1\text{-}C_4)$-alkyl-, $(C_1\text{-}C_4)$-alkyl-O-, $(C_3\text{-}C_7)$-cycloalkyl-O-, $(C_3\text{-}C_7)$-cycloalkyl-$(C_1\text{-}C_4)$-alkyl-O-, Ar-O- and Ar-$(C_1\text{-}C_4)$-alkyl-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen, fluorine and $(C_1\text{-}C_6)$-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a $(C_3\text{-}C_7)$-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and $(C_1\text{-}C_4)$-alkyl;

R^{11}, R^{12}, R^{13} and R^{14} are independently of each other selected from the series consisting of hydrogen and $(C_1\text{-}C_4)$-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two

identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-, cyano and (C_1-C_4)-alkyl-O-;

V is selected from the series consisting of R^{12}-N(R^{13})-, and in this case G and M are not present, or
V is selected from the series consisting of -N(R^{14})-, -N(R^{14})-(C_1-C_4)-alkyl-, -O- and -O-(C_1-C_4)-alkyl-, and in this case

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl, cyano and (C_1-C_4)-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14})- or -O-, and

M is selected from the series consisting of R^{11}-O-C(O)- and R^{12}-N(R^{13})-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof,
with the proviso that the compounds selected from the group
4-[[[2-[[5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methoxy]-2-methyl-1-oxopropyl]amino]methyl] benzoic acid,
4-[[[2-[[5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methoxy]-1-oxobutyl]amino]methyl] benzoic acid,
4-[[[2-[[5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methoxy]acetyl]amino]methyl] benzoic acid,

4-[[[2-[[1-(2,4-dichlorophenyl)-4-methyl-5-(4-methylphenyl)-1H-pyrazol-3-yl]methoxy]-2-methyl-1-oxypropyl]amino]methyl] benzoic acid,
4-[[[2-[(1,5-bis(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methoxy]-2-methyl-1-oxypropyl]amino]methyl] benzoic acid,
4-[[[2-[[5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methoxy]-1-oxopropyl]amino]methyl] benzoic acid,
2-[[1-(2,4-dichlorophenyl)-4-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]methoxy]-2-methyl propanamide,
2-[[1-(2,4-dichlorophenyl)-4-methyl-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-3-yl]methoxy]-2-methyl propanamide,
4-[[[2-[[1-(2,4-dichlorophenyl)-4-methyl-5-[4-trifluoromethoxy)phenyl]-1H-pyrazol-3-yl]methoxy]-2-methyl-1-oxopropyl]amino]methyl] benzoic acid, and
4-[[[2-[[5-(2,4-dichlorophenyl)-4-methyl-1-[4-trifluoromethyl)phenyl]-1H-pyrazol-3-yl]methoxy]-2-methyl-1-oxopropyl]amino]methyl] benzoic acid
are not falling within the claim.

2. A compound of the formula I according to claim 1, wherein

R^1 is selected from the series consisting of hydrogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, Ar and Ar-$(C_1\text{-}C_4)$-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, $(C_1\text{-}C_4)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, $(C_3\text{-}C_7)$-cycloalkyl-$(C_1\text{-}C_4)$-alkyl-, Ar, Ar-$(C_1\text{-}C_4)$-alkyl-, $(C_1\text{-}C_4)$-alkyl-O-, $(C_3\text{-}C_7)$-cycloalkyl-O-, $(C_3\text{-}C_7)$-cycloalkyl-$(C_1\text{-}C_4)$-alkyl-O-, Ar-O- and Ar-$(C_1\text{-}C_4)$-alkyl-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen and $(C_1\text{-}C_6)$-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a $(C_3\text{-}C_7)$-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and $(C_1\text{-}C_4)$-alkyl;

R^{11}, R^{12}, R^{13} and R^{14} are independently of each other selected from the series consisting of hydrogen and $(C_1$-$C_4)$-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-, cyano and $(C_1$-$C_4)$-alkyl-O-;

V is selected from the series consisting of -N(R^{14})-, -N(R^{14})-$(C_1$-$C_4)$-alkyl- and -O-$(C_1$-$C_4)$-alkyl-, and

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, cyano and $(C_1$-$C_4)$-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14})-, and

M is selected from the series consisting of R^{11}-O-C(O)- and R^{12}-N(R^{13})-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

3. A compound of the formula I according to one or more of claims 1 and 2, wherein

R^1 is selected from the series consisting of $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, Ar and Ar-$(C_1$-$C_4)$-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, $(C_1$-$C_4)$-alkyl, Ar, Ar-$(C_1$-$C_4)$-alkyl-, $(C_1$-$C_4)$-alkyl-O-, $(C_3$-$C_7)$-cycloalkyl-O-, Ar-O- and Ar-$(C_1$-$C_4)$-alkyl-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen and $(C_1$-$C_6)$-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a $(C_3$-$C_7)$-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

R^{11}, R^{12}, R^{13} and R^{14} are independently of each other selected from the series consisting of hydrogen and $(C_1$-$C_4)$-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl and $(C_1$-$C_4)$-alkyl-O-;

V is selected from the series consisting of -N(R^{14})- and -N(R^{14})-$(C_1$-$C_4)$-alkyl-, and

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl and $(C_1$-$C_4)$-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14})-, and

M is selected from the series consisting of R^{11}-O-C(O)- and R^{12}-N(R^{13})-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

4. A compound of the formula I according to one or more of claims 1 to 3, wherein

R^1 is selected from the series consisting of (C_1-C_4)-alkyl, Ar and Ar-(C_1-C_4)-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, (C_1-C_4)-alkyl, Ar, Ar-(C_1-C_4)-alkyl-, and Ar-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen and (C_1-C_6)-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a (C_3-C_7)-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

R^{11} and R^{14} are independently of each other selected from the series consisting of hydrogen and (C_1-C_4)-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different

substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl, (C_3-C_7)-cycloalkyl and (C_1-C_4)-alkyl-O-;

V is selected from the series consisting of -N(R^{14})- and -N(R^{14})-(C_1-C_4)-alkyl-, and

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl and (C_1-C_4)-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14}), and

M is R^{11}-O-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

5. A compound of the formula I according to one or more of claims 1 to 4, wherein

R^1 is selected from the series consisting of (C_1-C_4)-alkyl, Ar and Ar-(C_1-C_4)-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, (C_1-C_4)-alkyl, Ar- and Ar-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen and (C_1-C_6)-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a $(C_3$-$C_7)$-cycloalkane ring which is unsubstituted or substituted by one or more fluorine substituents;

R^{11} and R^{14} are independently of each other selected from the series consisting of hydrogen and $(C_1$-$C_4)$-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl and $(C_1$-$C_4)$-alkyl-O-;

V is selected from the series consisting of $-N(R^{14})-$ and $-N(R^{14})-(C_1$-$C_4)$-alkyl-,

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl and $(C_1$-$C_4)$-alkyl-O-, provided that G is not a direct bond if V is $-N(R^{14})$, and

M is R^{11}-O-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

6. A compound of the formula I according to one or more of claims 1 to 5, which is selected from the series consisting of

4-({2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid,
4-({2-[1-(2-Chloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid,
4-({2-[1-(4-Chloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-2-methyl-propionylamino}-methyl)-benzoic acid,
4-{2-[1-(2,4-Dichloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-propionylamino}-benzoic acid,
4-{2-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazol-3-ylmethoxy]-3-methyl-butyrylamino}-benzoic acid,
4-{2-[1-(4-Chloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-propionylamino}-benzoic acid,
4-[2-(3-Naphthalen-2-yl-1-phenyl-1H-pyrazol-4-ylmethoxy)-propionylamino]-benzoic acid,
4-{2-[1-(2-Chloro-phenyl)-4-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-ylmethoxy]-propionylamino}-benzoic acid,
4-[2-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethoxy)-propionylamino]-benzoic acid,
4-[2-(1,3-Diphenyl-1H-pyrazol-4-ylmethoxy)-propionylamino]-benzoic acid,
4-{2-[1-Benzyl-3-(3-methoxy-phenyl)-1H-pyrazol-4-ylmethoxy]-propionylamino}-benzoic acid,
4-{2-[5-(4-Fluoro-phenoxy)-1-methyl-3-phenyl-1H-pyrazol-4-ylmethoxy]-propionylamino}-benzoic acid,
4-{2-[3-(4-Cyclohexyl-phenyl)-1-phenyl-1H-pyrazol-4-ylmethoxy]-propionylamino}-benzoic acid,
4-[2-(1-Phenyl-3-thiophen-2-yl-1H-pyrazol-4-ylmethoxy)-propionylamino]-benzoic acid, and
4-[2-(1,5-Diphenyl-1H-pyrazol-3-ylmethoxy)-propionylamino]-benzoic acid,
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

7. A compound of the formula I or a pharmaceutically acceptable salt thereof for use as medicament



I

wherein

R^1 is selected from the series consisting of hydrogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, $(C_3\text{-}C_7)$-cycloalkyl-$(C_1\text{-}C_4)$-alkyl-, Ar and Ar-$(C_1\text{-}C_4)$-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, halogen, $(C_1\text{-}C_4)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, $(C_3\text{-}C_7)$-cycloalkyl-$(C_1\text{-}C_4)$-alkyl-, Ar, Ar-$(C_1\text{-}C_4)$-alkyl-, $(C_1\text{-}C_4)$-alkyl-O-, $(C_3\text{-}C_7)$-cycloalkyl-O-, $(C_3\text{-}C_7)$-cycloalkyl-$(C_1\text{-}C_4)$-alkyl-O-, Ar-O- and Ar-$(C_1\text{-}C_4)$-alkyl-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen, fluorine and $(C_1\text{-}C_6)$-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a $(C_3\text{-}C_7)$-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and $(C_1\text{-}C_4)$-alkyl;

R^{11}, R^{12}, R^{13} and R^{14} are independently of each other selected from the series consisting of hydrogen and $(C_1\text{-}C_4)$-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different

substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-, cyano and $(C_1$-$C_4)$-alkyl-O-;

V is selected from the series consisting of R^{12}-N(R^{13})-, and in this case G and M are not present, or
V is selected from the series consisting of -N(R^{14})-, -N(R^{14})-$(C_1$-$C_4)$-alkyl-, -O- and -O-$(C_1$-$C_4)$-alkyl-, and in this case

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, cyano and $(C_1$-$C_4)$-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14})- or -O-, and

M is selected from the series consisting of R^{11}-O-C(O)- and R^{12}-N(R^{13})-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof.

8. A compound of the formula I or a pharmaceutically acceptable salt thereof



I

wherein

R^1 is selected from the series consisting of hydrogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-, Ar and Ar-$(C_1$-$C_4)$-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-, Ar, Ar-$(C_1$-$C_4)$-alkyl-, $(C_1$-$C_4)$-alkyl-O-, $(C_3$-$C_7)$-cycloalkyl-O-, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-O-, Ar-O- and Ar-$(C_1$-$C_4)$-alkyl-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen, fluorine and $(C_1$-$C_6)$-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a $(C_3$-$C_7)$-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

R^{11}, R^{12}, R^{13} and R^{14} are independently of each other selected from the series consisting of hydrogen and $(C_1$-$C_4)$-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-, cyano and $(C_1$-$C_4)$-alkyl-O-;

V is selected from the series consisting of R^{12}-N(R^{13})-, and in this case G and M are not present, or
V is selected from the series consisting of -N(R^{14})-, -N(R^{14})-$(C_1$-$C_4)$-alkyl-, -O- and -O-$(C_1$-$C_4)$-alkyl-, and in this case

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents

selected from the series consisting of halogen, (C_1-C_4)-alkyl, cyano and (C_1-C_4)-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14})- or -O-, and

M is selected from the series consisting of R^{11}-O-C(O)- and R^{12}-N(R^{13})-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof,

for use in the treatment of a disease responsive to the inhibition of the LPA receptor LPAR5 or the reduction or inhibition of platelet aggregation or thrombus formation or the reduction or inhibition of activation of mast cells or the reduction or inhibition of activation of microglial cells.

9. A compound of the formula I or a pharmaceutically acceptable salt thereof



I

wherein

R^1 is selected from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-, Ar and Ar-(C_1-C_4)-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, halogen, (C_1-C_4)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-,

Ar, Ar-(C_1-C_4)-alkyl-, (C_1-C_4)-alkyl-O-, (C_3-C_7)-cycloalkyl-O-, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-O-, Ar-O- and Ar-(C_1-C_4)-alkyl-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen, fluorine and (C_1-C_6)-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a (C_3-C_7)-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

R^{11}, R^{12}, R^{13} and R^{14} are independently of each other selected from the series consisting of hydrogen and (C_1-C_4)-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-, cyano and (C_1-C_4)-alkyl-O-;

V is selected from the series consisting of R^{12}-N(R^{13})-, and in this case G and M are not present, or
V is selected from the series consisting of -N(R^{14})-, -N(R^{14})-(C_1-C_4)-alkyl-, -O- and -O-(C_1-C_4)-alkyl-, and in this case

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl, cyano and (C_1-C_4)-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14})- or -O-, and

M is selected from the series consisting of R^{11}-O-C(O)- and R^{12}-N(R^{13})-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof,

for use in the treatment of thromboembolic diseases, deep vein thrombosis, venous or arterial thromboembolism, thrombophlebitis, coronary or cerebral arterial thrombosis, cerebral embolism, renal embolism, pulmonary embolism, disseminated intravascular coagulation, cardiovascular disorders, transient ischemic attacks, strokes, acute myocardial infarction, unstable angina, chronic stable angina, peripheral vascular disease, preeclampsia/eclampsia, thrombotic cytopenic purpura, inflammatory disorders, hyperalgesia, asthma, multiple sclerosis, inflammatory pain, angiogenesis, atherothrombosis, allergic responses, or restenoses.

10. A compound of the formula I or a pharmaceutically acceptable salt thereof



I

wherein

R^1 is selected from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-, Ar and Ar-(C_1-C_4)-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, halogen, (C_1-C_4)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-,

Ar, Ar-(C_1-C_4)-alkyl-, (C_1-C_4)-alkyl-O-, (C_3-C_7)-cycloalkyl-O-, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-O-, Ar-O- and Ar-(C_1-C_4)-alkyl-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen, fluorine and (C_1-C_6)-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a (C_3-C_7)-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

R^{11}, R^{12}, R^{13} and R^{14} are independently of each other selected from the series consisting of hydrogen and (C_1-C_4)-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-, cyano and (C_1-C_4)-alkyl-O-;

V is selected from the series consisting of R^{12}-N(R^{13})-, and in this case G and M are not present, or
V is selected from the series consisting of -N(R^{14})-, -N(R^{14})-(C_1-C_4)-alkyl-, -O- and -O-(C_1-C_4)-alkyl-, and in this case

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, (C_1-C_4)-alkyl, cyano and (C_1-C_4)-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14})- or -O-, and

M is selected from the series consisting of R^{11}-O-C(O)- and R^{12}-N(R^{13})-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof,

for use in the treatment of abnormal thrombus formation, acute myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication, bypass grafting of the coronary or peripheral arteries, vessel luminal narrowing, restenosis post coronary venous angioplasty, maintenance of vascular access patency in long-term hemodialysis patients, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee or hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulatopathy occurring in vascular systems during septic shock, viral infections or cancer.

11. A compound of the formula I or a pharmaceutically acceptable salt thereof



I

wherein

R^1 is selected from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl-, Ar and Ar-(C_1-C_4)-alkyl-;

R^2 and R^3 are independently of each other selected from the series consisting of hydrogen, halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-, Ar, Ar-$(C_1$-$C_4)$-alkyl-, $(C_1$-$C_4)$-alkyl-O-, $(C_3$-$C_7)$-cycloalkyl-O-, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-O-, Ar-O- and Ar-$(C_1$-$C_4)$-alkyl-O-,

R^4 and R^5 are independently of each other selected from the series consisting of hydrogen, fluorine and $(C_1$-$C_6)$-alkyl,

or the groups R^4 and R^5 together with the carbon atom carrying them form a $(C_3$-$C_7)$-cycloalkane ring which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and $(C_1$-$C_4)$-alkyl;

R^{11}, R^{12}, R^{13} and R^{14} are independently of each other selected from the series consisting of hydrogen and $(C_1$-$C_4)$-alkyl;

Ar is selected from the series consisting of phenyl, naphthyl and an aromatic, 5-membered or 6-membered, monocyclic heterocycle which comprises one or two identical or different ring heteroatoms selected from the series consisting of N, O and S, which are all unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_4)$-alkyl-, cyano and $(C_1$-$C_4)$-alkyl-O-;

V is selected from the series consisting of R^{12}-N(R^{13})-, and in this case G and M are not present, or
V is selected from the series consisting of -N(R^{14})-, -N(R^{14})-$(C_1$-$C_4)$-alkyl-, -O- and -O-$(C_1$-$C_4)$-alkyl-, and in this case

G is selected from the series consisting of a direct bond and phenylene which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, cyano and $(C_1$-$C_4)$-alkyl-O-, provided that G is not a direct bond if V is -N(R^{14})- or -O-, and

M is selected from the series consisting of R^{11}-O-C(O)- and R^{12}-N(R^{13})-C(O)-;

wherein all alkyl groups are unsubstituted or substituted by one or more fluorine substituents, and all cycloalkyl groups are unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C_1-C_4)-alkyl;

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof,

for use in the treatment of inflammatory pain, asthma, angiogenesis, demyelating diseases of the central nervous system or the peripheral nervous system, multiple sclerosis, transverse myelitis, optic neuritis, Devic's disease, Guillain-Barre syndrome or chronic inflammatory demyelinating polyneuropathy.

12. A pharmaceutical composition comprising a compound of the formula I or a pharmaceutically acceptable salt thereof according to one or more of claims 1 to 6, and a pharmaceutically acceptable carrier.